Solventum : Fact Sheet (SOLV Q1 2025 Fact Sheet)

Published: 2025-05-09 12:41:05 ET SOLV

Published on 05/09/2025 at 12:41

Solventum at a Glance

At Solventum, we enable better, smarter, safer healthcare to improve lives. Across

our businesses - Medical Surgical, Dental Solutions, Health Information Services (HIS) and Puriflcation & Filtration (P&F) - we have strong positions in diverse and growing markets, trusted and recognized brands, and global commercial scale and reach.

70+

year history of innovation

6,500+

patents issued

20,000+

employees1

100,000+

customers and channel partners globally in 90+ countries

Business Segments at a Glance

Total company

sales2

Addressable

market size

(2024)3

Expected

market growth rate CAGR

Growth

Driver

(2025-2029)

MedSurg

Provides advanced wound care, infection prevention and surgical supplies that are intended to accelerate healing, prevent complications and lower the total cost of care globally

56%

$~31B

4-5%

Negative Pressure Wound Therapy

I.V. Site Management

Sterilization Assurance

Dental Solutions

Provides the most comprehensive dental solutions for patients to enjoy healthy, beautiful smiles through game-changing innovation

16%

$~19B

3-5%

Core Restoratives

HIS

Delivers innovative software solutions and services, designed to eliminate revenue cycle waste, create more time to care and support the shift to value-based care

16%

$~10B

5-6%

Revenue Cycle Management

P&F

Provides fllters and membranes for use in the manufacturing of biopharmaceutical and medical

technologies, microelectronics and food and beverage products, as well as flltration for cleaner drinking water

On Feb. 25, 2025, we announced the sale of our Puriflcation & Filtration business to Thermo Fisher Scientiflc Inc. We expect to close the transaction by the end of flscal year 2025.

Employees and patents issued excludes P&F segment

Calculated as % of Q1 2025 net sales

Market size and Market growth informed by management estimates, primary market data, third-party industry reports, peer reporting, and external consulting flrms

*

Q1 Financial Highlights

$2.1B

+2.6% total sales growth

+4.3% organic sales growth

$0.78

Four consecutive quarters

of positive growth and

sequential

*See non-GAAP flnancial measures and reconciliation schedules included in our Earnings Release dated May 8, 2025, which can be found on our investor relations website

$1.34

$29M

improvement

Segment Highlights

Strong Progress Propelled by Growth Drivers

+3.4% +6.0%

total sales growth organic

driving adoption of V.A.C. Peel and Place Dressing and key customer conversions in I.V. Site Management

(2.1%)

total sales growth

+0.4%

organic

with positive traction in Core Restoratives

+3.6%

total sales growth

+3.9%

organic

advancing Revenue Cycle Management through

autonomous coding

(0.9%)

total sales growth

+2.2%

organic

with robust demand for bioprocessing solutions reflecting

value of business' differentiated technology

Updated 2025 Guidance

Reflects Strong Momentum4

increased 50 bps

+1.5% to +2.5%

$5.45 to $5.65

(no change)5

$450M to $550M

Note: Guidance is for the whole company, including the Puriflcation and Filtration business, which is held for sale until the transaction closes, expected before the end of the year.

Note: Strong performance in Q1 and expected business momentum, combined with the reduced expected

impact of foreign exchange and other mitigating items, are expected to enable Solventum to absorb any evolving trade policy impact within our

prior EPS guidance range.

This communication and other materials Solventum has flled or will flle with the U.S. Securities & Exchange Commission (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," or other words of similar meaning. All statements that

reflect Solventum's expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, forecasts relating to discussions of future operations and flnancial performance (including volume growth, pricing, sales and earnings per share growth and cash flows) and statements regarding Solventum's strategy for growth, future product development, regulatory clearances and approvals, competitive position and expenditures. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and changes in circumstances. Actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. Solventum assumes no obligation to update or revise such statement, whether as a result of new information, future events or otherwise, except as required by applicable law. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's Annual Report on Form 10-K for the year ended December 31, 2024. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

In addition to reporting flnancial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. These non-GAAP flnancial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash.

Solventum calculates forward-looking non-GAAP flnancial measures, including organic sales growth, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted earnings per share, and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP flnancial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP flnancial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum's results in accordance with GAAP.

The Q1 2025 flnancial statements and flnancial information, including reconciliations of non-GAAP flnancial measures, are available on Solventum's website: investors.solventum.com.

Disclaimer

Solventum Corporation published this content on May 09, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 09, 2025 at 16:40 UTC.